A Case of Dasatinib-Induced Keratosis Pilaris

Research output: Contribution to journalArticlepeer-review


Dasatinib is a second-generation tyrosine kinase inhibitor (TKI) indicated for treatment of chronic myeloid leukemia (CML). Dasatinib targets several proteins specific to cancer pathogenesis such as Bcr-Abl, Src, c-kit and PDGFRb. Cutaneous reactions are a well-documented side effect of many TKIs, however, there are limited reports and characterization of dasatinib induced rash. We report a case of keratosis pilaris and follicular epithelial thinning in a 19-year-old patient one month after beginning dasatinib for treatment of CML. This report suggests a possible role of dasatinib in the induction of epithelial follicular instability via reduced Src activity and subsequent down regulation of EGFR.

Original languageEnglish (US)
Pages (from-to)625-630
Number of pages6
JournalSKIN: Journal of Cutaneous Medicine
Issue number1
StatePublished - Jan 10 2023

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'A Case of Dasatinib-Induced Keratosis Pilaris'. Together they form a unique fingerprint.

Cite this